Panobinostat-d4 (hydrochloride)

Panobinostat-d4 (hydrochloride)

• UNSPSC Description: Panobinostat-d4 (hydrochloride) is deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].
• Target Antigen: Apoptosis; Autophagy; HDAC; HIV; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Anti-infection;Apoptosis;Autophagy;Cell Cycle/DNA Damage;Epigenetics;Others
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Solubility: 10 mM in DMSO
• Smiles: ONC(/C=C/C(C([2H])=C1[2H])=C([2H])C([2H])=C1CNCCC2=C(C)NC3=CC=CC=C23)=O.Cl
• Molecular Weight: 389.91
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Banerjee NS, et al. Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification. Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):E11138-E11147.|[3]Barton K, et al. Broad activation of latent HIV-1 in vivo. Nat Commun. 2016;7:12731. Published 2016 Sep 8.|[4]Crisanti MC, et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther. 2009 Aug;8(8):2221-31.|[5]Ocio EM, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2010 May;95(5):794-803.|[6]Scuto A, et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood. 2008 May 15;111(10):5093-100.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported